PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"
Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer
Marketwire - Mon Aug 19, 12:27AM CDT
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team. In this newly created role, Dr Menrad will be responsible for developing and executing the Company's research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team. Dr Menrad will report directly to Andrew Kay, Algeta's President & CEO, and takes up his position immediately.
ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY
Thomson Reuters ONE - Thu Jul 18, 3:11AM CDT
Activaero GmbH / ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings (the "Transparency Law"
Marketwire - Fri Mar 08, 11:45AM CST
Ablynx (EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(R), announces today that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"